SCD Stem Cell Mobilization and Apheresis Using Motixafortide

Sickle Cell Disease Clinical Trial

Official title:

Sickle Cell Disease Stem Cell Mobilization and Apheresis Using Motixafortide

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06442761
• Other study ID #: SCDSTEMM
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: July 2024
• Est. completion date: July 2026

Study information

• Verified date: June 2024
• Source: St. Jude Children's Research Hospital
• Contact: Alexis Leonard, MD
• Phone: 866-278-5833
• Email: referralinfo[@]stjude.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use.

PRIMARY OBJECTIVE

• To characterize the safety and tolerability of motixafortide in participants with SCD as determined by the incidence of adverse events (AEs).

SECONDARY OBJECTIVES

• To characterize the efficacy of a single dose (Part A) or two doses (Part B) of motixafortide for hematopoietic stem cell (HSC) mobilization and apheresis collection in participants with SCD as determined by the yield of CD34+ cells (CD34+ cells/kg).

• To measure the mobilization effects of single-day (Part A) or daily dosing (Part B) dosing with motixafortide in the peripheral blood in participants with SCD as determined by peak peripheral blood CD34+ counts

• To recommend a phase 2 dosing strategy based on safety, efficacy, and mobilization effects

Description:

This study is divided into 2 parts. Participants will be assigned to a part based on when they enroll. Early in the study, participants will be assigned to part A. Later in the study, participants will be assigned to part B. In both parts, participants will receive the study drug, motixafortide, by an injection under the skin. About 8 hours after the injection, stem cells will be collected. Participants will follow-up within 7-10 days after the study drug and stem cell collection. Study staff will contact participants about 30 days after the last drug dose administration.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 15
• Est. completion date: July 2026
• Est. primary completion date: January 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants with severe sickle cell disease (SCD) who are =18 years of age and willing to donate autologous hematopoietic stem cells (HSCs) for advancing future gene therapy for SCD after collection of back-up product. Severe SCD, for the purpose of this study, will be defined as participants who are receiving chronic transfusion therapy due to SCD related complications or are eligible for or currently enrolled on an allogeneic transplant protocol.

• Participant must have a documented diagnosis of SCD with documentation of SCD genotype by medical history

• Participants should either have a central line in place or be able to undergo apheresis without the necessity of the insertion of a central venous catheter

• ECOG performance status/Karnofsky score/Lansky score >80

• White blood cell (WBC) count >3.0 x 10^9/L, absolute neutrophil count (ANC) >1.0 x 10^9/L, and platelet count >150 x 10^9/L, and hemoglobin >7.0 gm/dL

• Adequate renal function defined as serum/plasma creatinine < 1.5 mg/dL and an estimated glomerular filtration rate (eGFR) of at least 60 mL/min/1.73 m^2 based on the CKD-Epi equation or the St. Jude equation.

• Adequate liver function defined as direct bilirubin < 2.5 times the upper limit of normal range; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5 times the upper limit of normal range.

• Participant's cardiac function (i.e., ejection fraction >40%) and pulmonary status (i.e., no evidence of pulmonary hypertension) must be sufficient to undergo apheresis, as assessed by the Principal Investigator and an independent physician evaluating the participant.

• Negative serologic tests for syphilis, hepatitis B and C, HIV, and HTLV-1/II

• Feasible manual or automated exchange transfusion plan to achieve hemoglobin S (HbS) near 30% within one week of mobilization

• Female participants of childbearing age should have a negative serum pregnancy test within one week of beginning motixafortide administration.

• Participants of childbearing potential should agree to use of a highly effective form of contraception during treatment and for at least 1 month after the last dose of motixafortide. Women of childbearing potential must agree to use 2 methods of effective contraception: One barrier method (e.g. diaphragm, or condom or sponge, each of which are to be combined with a spermicide) and one hormonal method, unless she uses a highly effective method. Highly effective methods of contraception include:

• Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, transdermal

• Progestogen-only hormonal contraception associated with inhibition of ovulation:

oral, injectable, implantable

• Intrauterine device (IUD)

• Intrauterine hormone-releasing system (IUS)

• Bilateral tubal occlusion

• Vasectomised partner

• Sexual abstinence.

Exclusion Criteria:

• Emergency room admission or hospitalization in the past 14 days prior to first dose of study drug

• Major surgery in the past 30 days prior to first dose of study drug

• Active and painful splenomegaly or splenomegaly (size greater than upper limit of normal on examination).

• Participant who, by medical history, requires rare donor registry RBC units for transfusion, or is unable to receive routine transfusion. Eligible study participants must have undergone prior work-up for the presence of red cell alloantibodies and confirmation of available compatible blood product support

• Known allergy to or contraindication for motixafortide administration, or medications routinely administered during apheresis

• Participant who has had a prior autologous or allogeneic transplantation, inclusive of gene therapy

• Active viral, bacterial, fungal, or parasitic infection.

• History of cancer, excluding squamous carcinoma of the skin and cervical carcinoma in situ.

• Participant who has received experimental therapy within 4 weeks prior to providing informed consent

• Poorly controlled diabetes mellitus, as assessed by the Investigator

• Concomitant treatment with alternative investigational agent unable to be held for 30 days

• Unwillingness to use a highly effective method of contraception for 1 month after motixafortide

• Pregnancy

• Inability or unwillingness of research participant or legal guardian/ representative to give written informed consent.

• Inability or unwillingness of research participant to hold hydroxyurea for 30 days prior to first dose of study drug

Related Conditions & MeSH terms

• Anemia, Sickle Cell
• Sickle Cell Disease

Intervention

Drug:
• Motixafortide
Given Subcutaneously (under the skin).

Locations

Country	Name	City	State
United States	St. Jude Children's Research Hospital	Memphis	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
St. Jude Children's Research Hospital	BioLineRx, Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the safety and tolerability of motixafortide in participants with sickle cell disease (SCD) as determined by the incidence of adverse events.		0 - 30 days
Secondary	To determine the yield of CD34+ cells/kg after a single or daily dose of motixafortide in participants with SCD.		1 - 2 days
Secondary	To determine the mobilization effects as determined by peripheral blood CD34+ counts/uL after a single or daily dose of motixafortide in participants with SCD.		1 - 2 days
Secondary	To recommend a phase 2 dosing strategy of one or two doses motixafortide in participants with SCD based on the incidence of adverse events		through study completion, an average of 1 year
Secondary	To recommend a phase 2 dosing strategy for timing of apheresis based on peripheral blood CD34+ counts/uL after motixafortide administration in participants with SCD		through study completion, an average of 1 year

External Links

•   Clinical Trials Open at St. Jude
•   St. Jude Children's Research Hospital